---
title: "Obefazimod (ABX464) in Ulcerative colitis: ABX464-102"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: ABX464-102. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 52 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence/abx464-102"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: ABX464-102

<a id="heading-3.1.7"></a>

## 3.1.7 ABX464-102

<a id="heading-3.1.7.1"></a>

### 3.1.7.1 Objective

<a id="topic-3.1.7.1-1"></a>

#### Purpose stated in the ClinicalTrials.gov record

> “This study is an open-label study aiming at evaluating the long-term safety and the efficacy profile of ABX464 given once a day (o.d) at 50 mg in subjects who have been previously enrolled in the ABX464-101 clinical study (induction study) and who are willing to continue their treatment.”
> “A Follow-up Phase IIa Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 Given at 50 mg Once Daily in Subjects With Moderate to Severe Active Ulcerative Colitis.”

Source: [ClinicalTrials.gov NCT03368118](https://clinicaltrials.gov/study/NCT03368118)

<a id="topic-3.1.7.1-2"></a>

#### Primary, secondary, and echocardiography objectives in the protocol

> “The primary objective of the study is to evaluate the long-term safety of ABX464 given at 50 mg once daily in subjects with Moderate to Severe Active Ulcerative Colitis.”
> “To evaluate the long-term effect of ABX464 on clinical and endoscopic remission in subjects with Moderate to Severe Active Ulcerative Colitis assessed by the MCS.”
> “To evaluate the long-term effect of ABX464 on inflammatory markers (CRP, Calprotectin and ESR)”
> “To evaluate the effect of ABX464 on cardiac function as assessed through echocardiograms.”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="heading-3.1.7.2"></a>

### 3.1.7.2 Location and Study Date

<a id="topic-3.1.7.2-1"></a>

#### Study dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2018-01-20”
> “Primary Completion (Actual) 2022-07-12”
> “Study Completion (Actual) 2022-08-15”

Source: [ClinicalTrials.gov NCT03368118](https://clinicaltrials.gov/study/NCT03368118)

<a id="topic-3.1.7.2-2"></a>

#### Results posting date

> “Results First Posted 2025-03-05”

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="topic-3.1.7.2-3"></a>

#### Registered location

> “This study has 1 location”

Source: [ClinicalTrials.gov NCT03368118](https://clinicaltrials.gov/study/NCT03368118)

<a id="topic-3.1.7.2-4"></a>

#### Sites, study period, and EudraCT number in the protocol

> “Active sites from previous study (ABX464-101) located in Belgium, Hungary and Poland.”
> “Q4 2017 – Q3 2022”
> “2017-003284-35”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.7.2-5"></a>

#### Region of enrollment in the posted results

| Country | Participants |
| --- | --- |
| Belgium | “3” |
| Poland | “10” |
| Hungary | “9” |

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="heading-3.1.7.3"></a>

### 3.1.7.3 Study Design

<a id="topic-3.1.7.3-1"></a>

#### Design details in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Interventional model description | “open-label, follow-up study” |
| Masking | “None (Open Label)” |
| Phase | “Phase 2” |
| Enrollment (actual) | “22” |

Source: [ClinicalTrials.gov NCT03368118](https://clinicaltrials.gov/study/NCT03368118)

<a id="topic-3.1.7.3-2"></a>

#### Open-label treatment for 48 months regardless of induction assignment

> “All subjects will receive ABX464 given at 50 mg o.d irrespective of their previous treatment received in the ABX464-101 study (i.e. ABX464 or Placebo).”
> “The actual treatment received by a subject throughout the previous study (ABX464-101) will not be known at the time the subjects enter this follow-up study.”
> “Subjects will be treated with ABX464 for an overall period of 48 months. Subjects will be followed up weekly during the first month, every two weeks during the second month and then on a monthly basis until M24, then quarterly from M24 to M48.”
> “At M48, depending on their clinical response, eligible patients willing to continue study treatment will be offered to take part into a long term follow up study (ABX464-108 study).”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.7.3-3"></a>

#### Data safety monitoring board and cardiovascular safety committee

> “The DSMB will meet on a monthly basis until December 2019 and then quarterly from January 2020 onwards.”
> “An Independent Cardiovascular Safety Committee (ICVSC), comprised of 3 cardiologists with experience from drug development, will be formed as detailed in the Charter.”
> “Patients included with a history of cardiac ischemic disease and/or congestive heart failure will be discontinued from the study, will perform the End of Study Visit 4 weeks after last study drug administration and will then be treated according to the standard of care upon study treatment interruption.”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.7.3-4"></a>

#### Planned treatment duration of 12 months, January 2018, superseded in March 2019

> “ABX464-102 is a twelve-month open label follow-up study for patients with ulcerative colitis benefiting from the administration of ABX464 in the ABX464-101 study.”

Source: [Abivax press release, ABX464-102 authorization (2018)](https://ir.abivax.com/news-releases/news-release-details/abivax-initiate-long-term-extension-study-abx464-patients)

<a id="topic-3.1.7.3-5"></a>

#### Planned treatment duration of 24 months, March 2019, superseded in February 2022

> “These data have also convinced the study’s DSMB to recommend an additional 12-month extension to the study, increasing the total maintenance to 24 months.”

Source: [Abivax press release, phase 2a six-month maintenance data (2019)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-impressive-new-phase-2a-abx464-ulcerative)

<a id="heading-3.1.7.4"></a>

### 3.1.7.4 Eligibility Criteria

<a id="topic-3.1.7.4-1"></a>

#### Inclusion and exclusion criteria in the ClinicalTrials.gov record

> “Subjects previously enrolled in the ABX464-101 clinical study who have completed the initial 2-month treatment phase;”
> “Hemoglobin > 9.0 g dL-1;”
> “Creatinine clearance > 50 mL min-1 by the Cockcroft-Gault equation;”
> “Alkaline phosphatase, AST (SGOT) and ALT (SGPT) < 1.5 x ULN;”
> “Any condition, which in the opinion of the investigator, could compromise the subject's safety or the adherence to the study protocol.”
> “18 Years to 70 Years (Adult, Older Adult )”

Source: [ClinicalTrials.gov NCT03368118](https://clinicaltrials.gov/study/NCT03368118)

<a id="topic-3.1.7.4-2"></a>

#### Enrollment based on willingness and investigator judgement

> “The enrolment in this follow-up study will be based on the willingness of the subject to carry on his/her participation and also based on investigator’s judgement.”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.7.4-3"></a>

#### Enrollment of responders planned at authorization, January 2018

> “The new study will recruit patients from the ongoing ulcerative colitis proof-of-concept study (ABX464-101) who are responding to treatment with ABX464 into the 12-month open label follow-up study (ABX464-102).”

Source: [Abivax press release, ABX464-102 authorization (2018)](https://ir.abivax.com/news-releases/news-release-details/abivax-initiate-long-term-extension-study-abx464-patients)

<a id="heading-3.1.7.5"></a>

### 3.1.7.5 Treatment

<a id="topic-3.1.7.5-1"></a>

#### Intervention in the ClinicalTrials.gov record

> “All subjects will receive ABX464 at 50 mg o.d for an overall period of 48 months.”

Source: [ClinicalTrials.gov NCT03368118](https://clinicaltrials.gov/study/NCT03368118)

<a id="topic-3.1.7.5-2"></a>

#### Formulation

> “The study drug is formulated as hard gelatin, powder-filled capsules (size 01).”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.7.5-3"></a>

#### Allowed and prohibited concomitant medications

> “Oral 5-aminosalicylic acid at stable dose.”
> “Immunosuppressants in the form of azathioprine, 6-mercaptopurine, or methotrexate at stable dose.”
> “Topical corticosteroids and topical 5-aminosalicylic acid preparations.”
> “Drugs that could interact with ABX464 should be avoided especially the CYP1A2 inducers/inhibitors. The following CYP1A2 inducers/inhibitors are prohibited during the whole course of the study (ciprofloxacin, enoxacin, fluvoxamine, montelukast, phenytoin, rifampicin, ritonavir, teriflunomide).”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.7.5-4"></a>

#### Withdrawal for worsening ulcerative colitis

> “Worsening of the UC defined as a 2-point increase in the pMMS, with pMMS ≥ 4 on 2 separate occasions 7 day-apart and confirmed by an endoscopy sub score of 2 points or higher;”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="heading-3.1.7.6"></a>

### 3.1.7.6 Study Outcomes

<a id="heading-3.1.7.6.1"></a>

#### 3.1.7.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.7.6.1-1"></a>

##### Primary endpoint in the protocol

> “The primary endpoint of this study is defined as the number of incidences of treatment-emergent adverse events in the ABX464 treated subjects.”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.7.6.1-2"></a>

##### Registered outcome measures

> “Number of Treatment-emergent Adverse Events”
> “Through subject study treatment, up to 48 months”
> “Number of Subjects With Clinical Remission at Month 48”
> “SF-36 Quality of Life Questionnaire (SF-36 Physical Component)”

Source: [ClinicalTrials.gov NCT03368118](https://clinicaltrials.gov/study/NCT03368118)

<a id="topic-3.1.7.6.1-3"></a>

##### Adverse events of special interest

> “Due to safety signals in nonclinical toxicology studies, the following events are monitored as adverse events of special interest in ongoing and future studies with ABX464: anemia, liver function tests abnormalities, serious grade 3 infections and opportunistic infections, malignancies including non-melanoma skin cancers and cardiac events, including biomarkers (blood levels of AST, troponin, CPK and NT-proBNP).”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.7.6.1-4"></a>

##### Efficacy definitions in the statistical analysis plan

> “Clinical remission is achieved when all the following criteria are met in the components of the Mayo Score:”
> “rectal bleeding sub-score = 0”
> “central or local endoscopy sub-score <= 1”
> “Endoscopic improvement is achieved if the Mayo central endoscopic sub-score is 0 or 1.”
> “Endoscopic remission is defined as Mayo central endoscopic sub-score = 0.”
> “Worsening of the UC is defined as a 2-point increase from the screening TMS with 3 days of continuous rectal bleeding confirmed by flexible sigmoidoscopy with an endoscopy sub-score of 2 points or higher.”

Source: [Abivax ABX464-102 statistical analysis plan (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/SAP_001.pdf)

<a id="topic-3.1.7.6.1-5"></a>

##### Changes from the protocol in the statistical analysis plan

> “In the definition of clinical response (Section 11.3.1.6), Modified Mayo Score is used instead of Total Mayo Score for consistency with other Abivax studies.”
> “The echocardiography secondary endpoints will be included in a separate report.”

Source: [Abivax ABX464-102 statistical analysis plan (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/SAP_001.pdf)

<a id="topic-3.1.7.6.1-6"></a>

##### Clinical response definition in the posted results

> “reduction in Total Mayo Score (TMS) of at least 2 points and >= 30 percent from baseline with an accompanying decrease in rectal bleeding sub-score of >= 1 point or absolute rectal bleeding sub-score of <= 1 point.”

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="heading-3.1.7.7"></a>

### 3.1.7.7 Statistical Analysis Description

<a id="heading-3.1.7.7.1"></a>

#### 3.1.7.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.7.7.1-1"></a>

##### Planned sample size

> “Not applicable / Maximum 30 subjects (i.e. ABX464-101’s sample size)”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

> “Not applicable. All patients in this study are those who were included in the ABX464-101 study.”

Source: [Abivax ABX464-102 statistical analysis plan (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/SAP_001.pdf)

<a id="topic-3.1.7.7.1-2"></a>

##### Participants enrolled and analyzed in the posted results

| Measure | Quoted record |
| --- | --- |
| Enrollment (actual) | “22” |
| Overall number of baseline participants | “22” |
| Overall number of participants analyzed, each outcome | “22” |

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="heading-3.1.7.7.2"></a>

#### 3.1.7.7.2 Description of Analysis Sets

<a id="topic-3.1.7.7.2-1"></a>

##### Observed cases and non-responder imputation sets

> “The Observed Cases (OC) Set is defined as those subjects included in the study, who have received at least one dose of the study treatment. This set will use all data available at timepoints without any imputations for missing dichotomous values, and with Last Observation Carried Forward (LOCF) imputation (described in section 10.4) for missing continuous values.”
> “The OC Set will be used for all safety and efficacy analyses.”
> “Efficacy analyses will be repeated for the NRI Set.”
> “Observed Cases (OC) Set and Non-responder Imputation (NRI) Set are defined for populations instead of the populations defined in the protocol.”
> “No stratification or covariate adjustment will be used in this study.”

Source: [Abivax ABX464-102 statistical analysis plan (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/SAP_001.pdf)

<a id="topic-3.1.7.7.2-2"></a>

##### Descriptive efficacy analysis planned in the protocol

> “Analysis of safety will be performed on the safety data set consisting in all subjects who received at least one dose of ABX464 in the study.”
> “Efficacy results will be presented descriptively; proper tests will be performed if appropriate.”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.7.7.2-3"></a>

##### Month 12 interim analysis set

> “The interim analysis used the Month 12 Per Protocol (M12 PP) dataset which included all subjects that had a Month 12 visit. Of the 22 subjects, 3 subjects were excluded from the M12 PP Set: 2 subjects from the ABX464 induction group (one who withdrew due to lack of efficacy at M1 of the maintenance study and one who was lost to follow-up) and 1 subject from the placebo induction group (grade 2 headache at month 4), resulting in 19 subjects analyzed in the efficacy M12 PP set at baseline. Of the nineteen subjects in the set, sixteen had had a Month 12 endoscopy performed which forms part of the Total Mayo score (TMS).”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.7.7.2-4"></a>

##### Analysis populations in the posted results

> “Non responder Imputation (NRI) population”
> “Observed cases population”

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="heading-3.1.7.8"></a>

### 3.1.7.8 Results

<a id="heading-3.1.7.8.1"></a>

#### 3.1.7.8.1 Participant Disposition

<a id="topic-3.1.7.8.1-1"></a>

##### Participant flow in the posted results

| Milestone | ABX464 50 mg |
| --- | --- |
| Started | “22” |
| Completed | “11” |
| Not completed | “11” |

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="topic-3.1.7.8.1-2"></a>

##### Participants entering from the obefazimod and placebo induction groups

> “At the end of the completed 2 months induction treatment study, 22 Patients (15 previously treated with ABX464 and 7 on placebo) were enrolled into the open-label maintenance study with ABX464 50mg daily (ABX464-102) regardless of what treatment they had previously received.”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.7.8.1-3"></a>

##### Participants remaining on treatment through year 2

> “Out of 32 patients included in the active or placebo arm of the initial induction phase, 22 were enrolled in the 50mg once-daily open label ABX464 Phase 2a maintenance study. 19/22 patients stayed on treatment for 52 weeks and 16/19 patients completed the second year of ABX464 maintenance treatment.”

Source: [Abivax press release, phase 2a two-year maintenance data (2020)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-long-lasting-two-year-efficacy-and-safety-data)

<a id="topic-3.1.7.8.1-4"></a>

##### Participants completing year 3

> “15 out of the 22 patients who were initially enrolled into the phase 2a maintenance study in 2018, completed the third year of treatment with once-daily oral 50mg ABX464.”

Source: [Abivax press release, phase 2a three-year maintenance data (2021)](https://ir.abivax.com/news-releases/news-release-details/abivax-provides-update-abx464-clinical-data-and-development)

<a id="heading-3.1.7.8.2"></a>

#### 3.1.7.8.2 Baseline Characteristics

<a id="topic-3.1.7.8.2-1"></a>

##### Demographics in the posted results

| Characteristic | ABX464 50 mg (N=22) |
| --- | --- |
| Age, years, mean (SD) | “42.4(14.3)” |
| Female | “9” |
| Male | “13” |
| White | “22” |

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="topic-3.1.7.8.2-2"></a>

##### Clinical remission status at entry among participants remaining at month 12

> “Detailed analysis showed that of the 7/19 patients in clinical remission at the end of the two-month induction study, 5 patients were still in clinical remission at the end of the maintenance study and 2 patients missed endoscopy and could therefore not be assessed. Of the 12/19 patients NOT in clinical remission at the end of the induction study, 7 patients (58%) achieved clinical remission at the end of the maintenance study, while 4 patients had no remission and 1 had no endoscopy.”

Source: [Abivax press release, phase 2a 12-month maintenance data (2019)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-impressive-12-month-efficacy-and-safety-data)

<a id="heading-3.1.7.8.3"></a>

#### 3.1.7.8.3 Efficacy Results

<a id="topic-3.1.7.8.3-1"></a>

##### Month 48 outcomes with non-responder imputation in the posted results

| Outcome (N=22) | Quoted record |
| --- | --- |
| Participants with clinical response | “11” |
| Participants with clinical remission | “9” |
| Participants with endoscopic improvement | “9” |
| Participants with endoscopic remission | “6” |
| Change in total Mayo score, mean (SD) | “-3.0(3.4)” |
| Change in partial Mayo score, mean (SD) | “-2.2(2.4)” |
| Change in fecal calprotectin, µg/g, mean (SD) | “-299.69(472.28)” |
| Change in CRP, mg/L, mean (SD) | “2.29(4.82)” |
| Change in ESR, mm/hour, mean (SD) | “2.90(8.62)” |

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="topic-3.1.7.8.3-2"></a>

##### Ulcerative colitis worsening reported as an adverse event (post hoc)

> “Proportion of subjects with UC worsening based on adverse events”

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

| Measure | Quoted record |
| --- | --- |
| Overall number of participants analyzed | “22” |
| Participants with UC worsening | “7” |

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="topic-3.1.7.8.3-3"></a>

##### Month 12 interim results

> “A total of 19 patients completed the one year ABX464 open label maintenance study and showed good long-term safety and tolerability of 50mg given orally over 52 weeks.”
> “At month 12, an endoscopy to assess clinical remission status (the critical parameter for regulatory authorities) was performed in 16/19 patients. During treatment with ABX464, patients reduced their total Mayo Score (mean) from 8.7 to 1.9 (-78%), their endoscopic subscore from 2.3 to 0.25 (-89%) and the fecal calprotectin biomarker (median) from 1044 microg/g to 27.9 microg/g (-97%).”
> “All 16 patients with endoscopy showed an endoscopic subscore of 0 or 1, indicative of mucosal healing and in total 12/16 (75%) of the patients undergoing endoscopy achieved clinical remission.”

Source: [Abivax press release, phase 2a 12-month maintenance data (2019)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-impressive-12-month-efficacy-and-safety-data)

<a id="topic-3.1.7.8.3-4"></a>

##### Month 12 interim results stated in the protocol

> “Clinical remissions obtained at the end of the induction study were durable and the rates further improved during the maintenance phase, as additional subjects achieved clinical remission for 12 months treatment.”
> “All patients who had an endoscopy performed, had an endoscopic sub-score of 0 or 1. 12/16 patients were in clinical remission at month 12.”
> “Mean and median fecal calprotectin and CRP showed continued declines during the maintenance study, though the large variability and small patient numbers requires that the results should be interpreted with caution.”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.7.8.3-5"></a>

##### Month 24 interim results with central endoscopy reading

> “Readings for all endoscopies were performed centrally by independent reviewers. The data showed that 11/16 (69%) patients were in clinical remission and 15/16 (94%) benefited from a clinical response. 7/16 (44%) had endoscopic remission consisting of complete disappearance of colon/rectum lesions (endoscopic Mayo score=0). Median fecal calprotectin, the key biological marker of UC disease activity, which was normalized during the first year of treatment, remained at 31.6 µg/g (normal levels are below 50 µg/g).”
> “Especially as the central and independent endoscopy readings after two years confirm the good one-year maintenance results, where endoscopies were read locally.”
> “Stool frequency sub score = 0 or 1 and rectal bleeding sub score = 0 and endoscopy sub score = 0 or 1 (modified to exclude friability).”

Source: [Abivax press release, phase 2a two-year maintenance data (2020)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-long-lasting-two-year-efficacy-and-safety-data)

<a id="topic-3.1.7.8.3-6"></a>

##### Month 36 interim results

> “Among the 13 patients who underwent centrally read endoscopies at the completion of year 3, 11 patients (85%) were still in clinical remission, among which 7 patients (54%) had an endoscopic remission (endoscopic subscore=0) and 11 patients had an endoscopic improvement (endoscopic subscore=0 or 1).”

Source: [Abivax press release, phase 2a three-year maintenance data (2021)](https://ir.abivax.com/news-releases/news-release-details/abivax-provides-update-abx464-clinical-data-and-development)

Additional sources: [Vermeire et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33662385/)

<a id="heading-3.1.7.8.4"></a>

#### 3.1.7.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.7.8.4-1"></a>

##### SF-36 component scores at up to 24 months in the posted results

| Outcome (N=22, non-responder imputation) | Change from day 0, mean (SD) |
| --- | --- |
| SF-36 physical component | “4.82(4.23)” |
| SF-36 mental component | “6.38(3.40)” |

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="topic-3.1.7.8.4-2"></a>

##### SF-36 instrument and assessment schedule

> “Change from Day 0 up to 24 months in SF-36 Questionnaire scores; The SF-36 questionnaire is a self-administered questionnaire containing 36 items.”

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

> “SF-36 Questionnaire is assessed at the following visits: D28, D56/M2, and M3 to M24 on a monthly basis.”

Source: [Abivax ABX464-102 statistical analysis plan (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/SAP_001.pdf)

<a id="heading-3.1.7.8.5"></a>

#### 3.1.7.8.5 Safety Results

<a id="topic-3.1.7.8.5-1"></a>

##### Adverse event counts in the posted results

| Outcome (N=22) | Events |
| --- | --- |
| Treatment-emergent adverse events | “145” |
| Treatment-emergent serious adverse events | “3” |
| Treatment-emergent adverse events of special interest | “15” |
| Adverse events leading to investigational product discontinuation | “1” |
| Specific laboratory abnormalities, first 12 months | “17” |

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="topic-3.1.7.8.5-2"></a>

##### Deaths and serious adverse events in the posted results

| Measure | Affected / at risk (%) |
| --- | --- |
| All-cause mortality | “0/22 (0.00%)” |
| Serious adverse events, total | “3/22 (13.64%)” |
| Myocardial infarction | “1/22 (4.55%)” |
| Enteropathic spondylitis | “1/22 (4.55%)” |
| Benign ovarian tumor | “1/22 (4.55%)” |

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="topic-3.1.7.8.5-3"></a>

##### Investigator assessment of the serious adverse events

> “The event was considered not related to study treatment and resolved without sequelae 5 days after onset date. No action was taken with study treatment”
> “The subject admitted to hospital due to spondyloarthropathy caused by inflammatory bowel disease (HLA-B27+). The event considered not related to study treatment and resolved without sequelae. No action was taken with study treatment.”
> “subject underwent total hysterectomy. Event considered not related to study treatment and resolved without sequelae. Study treatment was temporarily discontinued.”

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="topic-3.1.7.8.5-4"></a>

##### Other adverse events in at least 3 participants

| Event | Affected / at risk (%) |
| --- | --- |
| Other (not including serious) adverse events, total | “20/22 (90.91%)” |
| Colitis ulcerative | “7/22 (31.82%)” |
| Abdominal pain | “5/22 (22.73%)” |
| Nasopharyngitis | “5/22 (22.73%)” |
| Diarrhoea | “4/22 (18.18%)” |
| Vomiting | “3/22 (13.64%)” |
| Headache | “3/22 (13.64%)” |

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="topic-3.1.7.8.5-5"></a>

##### Adverse event collection period

> “Adverse event were collected from first day of dosing (baseline) up to last safety visit (up to 49 months : 48 months on treatment and one month safety follow-up)”

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="topic-3.1.7.8.5-6"></a>

##### Sponsor statements on safety at month 12 and year 2

> “No severe or serious adverse reactions were reported. Most adverse events were of mild to moderate intensity.”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

> “ABX464 was safe and well tolerated and there were no serious adverse drug reactions reported. No patients were prematurely discontinued due to adverse event during this second year of ABX464 treatment.”

Source: [Abivax press release, phase 2a two-year maintenance data (2020)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-long-lasting-two-year-efficacy-and-safety-data)

Additional sources: [Vermeire et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33662385/)

<a id="heading-3.1.7.9"></a>

### 3.1.7.9 Study Limitations

<a id="topic-3.1.7.9-1"></a>

#### Summary

ABX464-102 was a single-group, open-label extension without a control group, in which 22 participants who completed ABX464-101 (15 previously assigned to obefazimod and 7 to placebo) received obefazimod 50 mg once daily, at sites in Belgium, Hungary, and Poland (3, 9, and 10 participants). Enrollment was based on participant willingness and investigator judgement, and the protocol set no sample size beyond a “Maximum 30 subjects”. The planned treatment period was 12 months in a 2018 press release, 24 months after a data safety monitoring board recommendation reported in 2019, and 48 months in the 2022 protocol. The primary endpoint was the number of treatment-emergent adverse events; efficacy results were to be “presented descriptively”. Eleven of 22 participants completed the study. Interim efficacy was reported among participants with an endoscopy at each timepoint (12 of 16 in clinical remission at month 12, 11 of 16 at month 24, and 11 of 13 at month 36); endoscopies were read locally at month 12 and centrally at month 24. In the posted non-responder imputation analysis, 9 of 22 participants were in clinical remission at month 48. The statistical analysis plan defines clinical response by the modified Mayo score, and the posted outcome description defines it by the total Mayo score. Seven of 22 participants had ulcerative colitis worsening reported as an adverse event. SF-36 was assessed only to month 24, and the echocardiography endpoints were moved to a separate report that was not located. All 22 participants were White.

Source: [ClinicalTrials.gov NCT03368118](https://clinicaltrials.gov/study/NCT03368118); [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results); [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf); [Abivax ABX464-102 statistical analysis plan (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/SAP_001.pdf); [Abivax press release, ABX464-102 authorization (2018)](https://ir.abivax.com/news-releases/news-release-details/abivax-initiate-long-term-extension-study-abx464-patients); [Abivax press release, phase 2a six-month maintenance data (2019)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-impressive-new-phase-2a-abx464-ulcerative); [Abivax press release, phase 2a two-year maintenance data (2020)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-long-lasting-two-year-efficacy-and-safety-data); [Abivax press release, phase 2a three-year maintenance data (2021)](https://ir.abivax.com/news-releases/news-release-details/abivax-provides-update-abx464-clinical-data-and-development)

Additional sources: [Vermeire et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33662385/)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
